Volatility and Risk
SCYNEXIS has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, CytoDyn has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.
Profitability
This table compares SCYNEXIS and CytoDyn’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SCYNEXIS | -599.05% | -41.02% | -26.14% |
| CytoDyn | N/A | N/A | -4.40% |
Insider & Institutional Ownership
54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 5.1% of CytoDyn shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by insiders. Comparatively, 0.5% of CytoDyn shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SCYNEXIS | $2.63 million | 11.89 | -$21.29 million | ($0.40) | -2.00 |
| CytoDyn | N/A | N/A | $3.74 million | $0.01 | 26.86 |
CytoDyn has lower revenue, but higher earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than CytoDyn, indicating that it is currently the more affordable of the two stocks.
Summary
CytoDyn beats SCYNEXIS on 6 of the 10 factors compared between the two stocks.
About SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
About CytoDyn
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
